KIDS

+ Watchlist + Portfolio

OrthoPediatrics Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.50
52-Week Range: $14.42 – $26.74
Market Cap: $684.86M
P/E (TTM): —
EPS (TTM): -1.68
Dividend Yield: —

Advanced Metrics

Price/Book: 1.99
PEG Ratio: —
Return on Equity: -11.36%
Return on Assets: -2.80%
Gross Margin: 73.65%
Operating Margin: -5.77%
Profit Margin: -15.72%
Current Ratio: 4.78
Debt/Equity: 0.32
Total Debt: $111.18M
Free Cash Flow: $3.19M
Revenue Growth: 15.40%
Earnings Growth: —
Enterprise Value: $757.21M

KIDS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$122.29M	$148.73M	$204.73M	$236.35M
Cost of Revenue	$31.63M	$37.48M	$56.13M	$63.69M
Gross Profit	$90.66M	$111.25M	$148.60M	$172.66M
Research & Development	$8.45M	$10.89M	$11.03M	$9.10M
Selling, General & Admin	$104.00M	$126.12M	$167.09M	$192.56M
Operating Expenses	$112.45M	$137.02M	$178.12M	$201.66M
Operating Income	-$21.79M	-$25.77M	-$29.52M	-$29.00M
EBITDA	-$8.69M	-$8.38M	-$10.44M	-$7.88M
Pretax Income	-$3.69M	-$21.31M	-$41.93M	-$39.19M
Income Tax	-$4.95M	-$338.00K	-$4.11M	$460.00K
Net Income	$1.26M	-$20.97M	-$37.82M	-$39.65M
Diluted EPS	0.06	-0.92	-1.64	-1.69
Diluted Shares	20.95M	22.68M	23.08M	23.46M

KIDS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.99M	$31.05M	$43.82M	$19.56M
Receivables	$24.80M	$34.62M	$42.36M	$53.84M
Inventory	$78.19M	$105.85M	$117.00M	$133.79M
Current Assets	$226.72M	$226.50M	$237.17M	$256.42M
Total Assets	$427.73M	$438.75M	$473.21M	$508.63M
Current Liabilities	$30.87M	$41.67M	$33.96M	$46.20M
Long-Term Debt	$763.00K	$9.91M	$72.96M	$99.82M
Total Debt	$907.00K	$10.06M	$73.12M	$99.99M
Total Liabilities	$49.08M	$61.72M	$118.64M	$162.03M
Retained Earnings	-$176.77M	-$197.74M	-$235.56M	-$275.21M
Shareholders' Equity	$378.65M	$377.02M	$354.57M	$346.60M
Working Capital	$195.85M	$184.83M	$203.21M	$210.22M
Net Debt	—	—	$29.30M	$80.43M

KIDS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$21.77M	-$27.05M	-$27.05M	-$4.85M
Capital Expenditure	-$10.03M	-$16.88M	-$14.26M	-$11.11M
Free Cash Flow	-$31.80M	-$43.92M	-$41.31M	-$15.96M
Depreciation & Amortisation	$13.10M	$17.39M	$19.08M	$21.12M
Stock-Based Compensation	$6.68M	$10.53M	$13.55M	$17.78M
Investing Cash Flow	-$113.37M	$41.68M	-$13.16M	-$43.63M
Financing Cash Flow	$135.97M	$7.30M	$53.13M	$23.98M
Net Change in Cash	$837.00K	$21.93M	$12.93M	-$24.50M

KIDS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$52.41M	$61.08M	$61.25M	$61.60M	$59.36M
Cost of Revenue	$14.15M	$17.06M	$15.98M	$16.50M	$15.97M
Gross Profit	$38.26M	$44.02M	$45.27M	$45.11M	$43.39M
Research & Development	$2.35M	$2.16M	$2.33M	$2.26M	$2.23M
Selling, General & Admin	$46.85M	$49.55M	$47.81M	$48.35M	$49.49M
Operating Expenses	$49.20M	$51.70M	$50.14M	$50.61M	$51.73M
Operating Income	-$10.94M	-$7.69M	-$4.87M	-$5.51M	-$8.34M
EBITDA	-$4.29M	-$778.00K	-$4.78M	$1.96M	-$3.04M
Pretax Income	-$10.46M	-$7.06M	-$11.90M	-$9.76M	-$10.86M
Income Tax	$196.00K	$49.00K	-$125.00K	$340.00K	-$171.00K
Net Income	-$10.66M	-$7.11M	-$11.77M	-$10.10M	-$10.69M
Diluted EPS	-0.46	-0.30	-0.50	-0.43	-0.45
Diluted Shares	23.23M	23.46M	23.57M	23.58M	23.69M

KIDS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$33.44M	$44.55M	$16.83M	$19.56M	$12.19M
Receivables	$43.99M	$53.80M	$51.27M	$53.84M	$54.43M
Inventory	$119.75M	$125.27M	$128.81M	$133.79M	$134.02M
Current Assets	$232.06M	$257.70M	$245.85M	$256.42M	$245.87M
Total Assets	$470.25M	$503.61M	$493.49M	$508.63M	$502.19M
Current Liabilities	$37.51M	$38.67M	$33.23M	$46.20M	$47.18M
Long-Term Debt	$73.03M	$97.00M	$99.17M	$99.82M	$100.39M
Total Debt	$73.19M	$97.17M	$99.34M	$99.99M	$100.56M
Total Liabilities	$123.10M	$148.09M	$144.18M	$162.03M	$163.48M
Retained Earnings	-$246.22M	-$253.34M	-$265.11M	-$275.21M	-$285.90M
Shareholders' Equity	$347.15M	$355.51M	$349.31M	$346.60M	$338.71M
Working Capital	$194.55M	$219.04M	$212.62M	$210.22M	$198.68M
Net Debt	$39.75M	$52.62M	$82.51M	$80.43M	$88.37M

KIDS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.16M	-$10.46M	-$581.00K	$10.35M	-$3.29M
Capital Expenditure	-$4.23M	-$3.44M	-$2.84M	-$599.00K	-$1.76M
Free Cash Flow	-$8.38M	-$13.91M	-$3.42M	$9.75M	-$5.05M
Depreciation & Amortisation	$5.05M	$5.17M	$5.30M	$5.60M	$5.72M
Stock-Based Compensation	$3.86M	$5.25M	$4.25M	$4.42M	$3.98M
Investing Cash Flow	-$5.99M	-$3.54M	-$26.84M	-$7.26M	-$3.79M
Financing Cash Flow	-$126.00K	$24.80M	-$282.00K	-$417.00K	-$614.00K
Net Change in Cash	-$10.27M	$10.79M	-$27.70M	$2.67M	-$7.69M

Market Snapshot

About

OrthoPediatrics Corp. is a medical device company focused exclusively on advancing the field of pediatric orthopedics. The company designs, develops, and markets anatomically appropriate implants and devices for children with orthopedic conditions. OrthoPediatrics serves pediatric orthopedic surgeons and hospitals worldwide with specialized products for fractures, deformity correction, and trauma.